Saturday 17 October 2026
Export NEUP’s income statement to Excel — free account
Neuphoria Therapeutics Inc.
NEUP Healthcare Biotechnology
Neuphoria Therapeutics Inc.’s revenue for fiscal 2026 (year ended June 2026) was $1.2 million, down 92.5% from fiscal 2025. In the quarter to June 2026, revenue fell 107.3%, EPS grew 83.6% and free cash flow grew 133.9%, each against the same quarter a year earlier.
3.30
0.01
−0.30%
Follow NEUP
| Jun '17 | Jun '18 | Jun '19 | Jun '20 | Jun '21 | Jun '22 | Jun '23 | Jun '24 | Jun '25 | Jun '26 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | — | 0.00 | 0.00 |
Altman Z-Score |
— | — | — | — | — | 1.06 | (8.42) | — | (7.14) | (7.55) |
P/S ratio |
558.54 | 558.54 | 558.54 | 558.54 | — | 1,463.61 | 574.69 | — | 0.74 | 1.23 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | — | 50.41 | 0.00 |
Altman Z″-Score (non-manufacturers) |
— | (9.91) | — | (18.17) | — | 0.07 | (17.76) | — | (16.04) | (14.70) |
P/Operating CF |
(135.99) | (135.99) | (135.99) | (135.99) | — | (39.96) | (14.99) | — | (3.21) | 15.83 |
Beneish M-Score |
— | — | — | — | — | — | (7.82) | — | — | 831.96 |
P/B ratio |
21.54 | 21.54 | 21.54 | 21.54 | — | 15.27 | 0.00 | — | 0.61 | 0.78 |
Price to Tangible BV |
40.60 | 40.60 | 40.60 | 40.60 | — | 25.41 | 0.00 | — | 2.07 | 1.13 |
EV/Sales |
543.25 | 543.25 | 543.25 | 543.25 | — | 1,408.25 | 543.36 | — | (0.12) | 0.02 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | — | 3.98 | 0.00 |
EV/Operating CF |
(80.32) | (80.32) | (80.32) | (80.32) | — | (19.13) | (4.49) | — | (24.05) | (0.02) |
EV/FCF |
(80.32) | (80.32) | (80.32) | (80.32) | — | (19.13) | (4.49) | — | (8.12) | (0.02) |
Quick Ratio |
3.84 | 2.60 | 1.69 | 0.91 | 12.74 | 12.02 | 4.57 | 3.33 | 3.39 | 27.33 |
Current Ratio |
3.92 | 2.70 | 1.82 | 1.01 | 13.10 | 12.46 | 4.87 | 3.45 | 3.56 | 27.85 |
Net Debt/EBITDA |
2.02 | 0.15 | (0.21) | (0.80) | 4.92 | 1.59 | 0.57 | 0.73 | 30.65 | 1.26 |
Debt/Assets |
0.00% | 32.94% | 34.10% | 35.51% | 1.28% | 0.82% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.46 | 1.26 | 1.11 | 0.96 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.25 | 0.12 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.56 | 0.04 |
Operating CF/Net income |
0.04 | 0.79 | 1.48 | 0.54 | 0.87 | 1.00 | 0.68 | 0.95 | (0.21) | 0.92 |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.16 | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Coverage |
(9.33) | (25.18) | 0.00 | (12.67) | (5.15) | (496.67) | (1,115.89) | — | — | — |
| (23.77%) | (85.08%) | (60.13%) | (48.22%) | (29.37%) | (41.08%) | (67.56%) | (78.44%) | (2.03%) | (61.70%) | |
| (9.20%) | (77.11%) | (16.91%) | (15.95%) | (20.26%) | (35.91%) | (56.31%) | (55.12%) | (1.31%) | (46.95%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | (24.03%) | (57.33%) | (138.68%) | (229.05%) | (14.97%) | (217.17%) |
Return on Tangible Assets |
(15.62%) | (98.84%) | (74.88%) | (637.95%) | (30.44%) | (56.58%) | (201.90%) | (165.40%) | (3.42%) | (66.23%) |
Average Days of Receivables |
195.77 | 874.84 | 4,539.58 | 23,295.91 | 0.00 | 9,390.97 | 10,508.55 | 0.00 | 0.28 | 252.85 |
Research and Development Expense of Revenue |
131.30% | 672.61% | 1,729.15% | 12,479.23% | 0.00% | 6,067.59% | 88,322.30% | 0.00% | 57.54% | 301.94% |
Selling, General and Administrative Expense of Revenue |
35.46% | 154.71% | 966.61% | 8,231.69% | 0.00% | 2,805.85% | 60,211.49% | 0.00% | 49.67% | 633.55% |
Intangible Assets out of Total Assets |
0.00 | 0.40 | 0.48 | 0.71 | 0.41 | 0.35 | 0.52 | 0.51 | 0.47 | 0.27 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 1,073.13% | 9,089.86% | 0.00% | 1.05% | 29.94% |
Graham Net Nets |
0.02 | 0.02 | 0.02 | 0.02 | — | 0.04 | 0.03 | — | 0.47 | 0.88 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.42 | — | 0.00 | 0.00 |
Earnings Yield |
(0.01%) | (0.01%) | (0.01%) | (0.01%) | — | (0.03%) | (0.10%) | — | (15.34%) | (115.33%) |
Free Cash Flow Yield |
(1.21%) | (1.21%) | (1.21%) | (1.21%) | — | (5.03%) | (21.06%) | — | 1.98% | (63.52%) |
Revenue per Share |
4.47 | 0.90 | 0.15 | 0.01 | 0.00 | 0.31 | 0.02 | 0.00 | 9.64 | 0.27 |
Operating CF per Share |
(0.06) | (4.79) | (3.22) | (0.76) | (15.61) | (25.20) | (21.54) | (17.64) | 0.05 | (2.81) |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.07 | 0.20 | 0.00 | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
(0.06) | (4.79) | (3.22) | (0.76) | (15.54) | (25.00) | (21.54) | (17.64) | 0.05 | (2.81) |
Cash per Share |
10.53 | 6.13 | 3.06 | 0.90 | 59.91 | 38.88 | 17.81 | 15.15 | 8.80 | 4.52 |
Shareholders Equity per Share |
9.81 | 4.08 | 3.47 | 2.50 | 98.55 | 65.93 | 32.38 | 21.02 | 11.71 | 5.60 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
9.81 | 4.08 | 3.47 | 2.50 | 98.55 | 65.93 | 32.38 | 21.02 | 11.71 | 5.60 |
Free Cash Flow |
(0.18) | (14.73) | (10.70) | (2.63) | (5.61) | (15.66) | (14.64) | (14.68) | 0.08 | (12.35) |
Working Capital |
31.22 | 16.77 | 7.92 | 0.04 | 21.34 | 27.90 | 10.59 | 9.36 | 10.82 | 20.31 |
Capital Expenditures |
(0.19) | (0.36) | (0.07) | (0.01) | 0.03 | 0.13 | — | — | — | — |
Net Current Asset Value |
8.35 | (9.03) | (8.41) | (9.21) | 18.13 | 24.24 | 6.77 | 3.04 | 5.45 | 16.96 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | — | 1.64 | 0.00 |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.66) | 0.00 | — | 0.00 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | — | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.67 | 0.61 | 0.68 | 2.32 | 208.34 | 211.82 | 265.28 | 331.50 | 236.75 | 0.00 |
Cash ROIC |
(0.23%) | (31.13%) | (31.01%) | (13.03%) | (9.72%) | (23.71%) | (42.91%) | (48.78%) | 0.23% | (27.78%) |
Accounts Receivable Turnover |
1.99 | 0.39 | 0.08 | 0.01 | 0.00 | 0.07 | 0.01 | 0.00 | 225.50 | 2.85 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | — | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | — | — | — | — |
Average Receivables |
7.14 | 7.14 | 6.38 | 4.07 | 1.44 | 2.88 | 2.67 | 0.28 | 0.07 | 0.41 |
Average Payables |
2.07 | 2.07 | 1.76 | 0.85 | 1.11 | 1.69 | 1.73 | 1.84 | 1.70 | 0.77 |
Average Inventory |
0.35 | 0.35 | 0.41 | — | — | — | — | — | — | — |
Average Assets |
56.44 | 24.10 | 42.86 | 30.56 | 32.08 | 43.96 | 37.97 | 28.11 | 28.12 | 28.65 |
Average Common Equity |
21.84 | 21.84 | 12.05 | 10.11 | 22.13 | 38.43 | 31.65 | 19.75 | 18.25 | 21.80 |
Columns are period end dates · fundamentals updated 2 Oct 2026